Atlas Trials

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

Clinical trial NCT07242352 · RECRUITING

Trial details

NCT number
NCT07242352
Sponsor
Women's Cancer Study Group GmbH
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Breast CancerHR+/HER2- Breast Cancer
Start date
2026-04-29
Primary completion
2033-09-30
Enrollment
1520

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.